construction of aav-rat-il4 and evaluation of its modulating effect on aβ (1-42)-induced proinflammatory cytokines in primary microglia and the b92 cell line by quantitative pcr assay

Background: interleukin-4 (il-4), as the most prominent anti-inflammatory cytokine, plays an important role in modulating microglial activation and inflammatory responses in alzheimer’s disease (ad), a chronic inflammatory disorder. objectives: the current study aimed to develop a new recombinant adeno-associated viral (raav) vector that delivers il-4 and then assess the counterbalancing effect of the new construct along with recombinant il-4 (ril-4) protein in in-vitro models of ad. materials and methods: the raav-il4 was originally prepared and then employed along with ril-4 protein to counter amyloid β (1-42)-induced proinflammatory cytokines in a primary microglia cell culture and the b92 rat microglia continuous cell line, using relative real-time pcr assay. results: aβ (1-42) stimulated the production of the proinflammatory cytokines il6, il1β, tnfα, and il18 in both the primary microglia cell culture and the b92 cell line. both the raav-il4 construct and the ril-4 protein were found to inhibit production of the most important aβ (1-42)-induced proinflammatory cytokine mrnas in the two types of cells with different patterns. conclusions: it seems that the new construct can serve as an appropriate option in the modulation of aβ-induced proinflammatory cytokine gene expression and microglia activation in patients affected by ad.